Pelvital, a leading women’s health company, announced the successful closing of an additional $2.32 million in its seed-plus funding round, closing the round out $500,000 oversubscribed at $5 million. The seed plus funding will be used to expedite the commercialization of Flyte, which Pelvital’s novel FDA-cleared revolutionary, accessible, and clinically proven treatment for stress urinary incontinence (SUI) and weakened pelvic floor muscles.
This funding round was led by Boomerang Ventures, a VC firm focused on transformative connected health. With this funding round, Pelvital welcomes new investors, including Pier 70 Ventures, Life Science Angels, Tech Coast Angels Orange County, and Blue Pacific Fund.
In connection with the funding round, Preetha Ram, PhD, Managing Partner at Pier 70 Ventures, joins the Pelvital Board of Directors.
Two published clinical trials validated Flyte’s safety, efficacy, and durability of treatment effect for women with SUI. Most recently, Pelvital published a paper in Therapeutic Advances in Urology, showing that 71% of study participants achieved dry or near dry conditions as evidenced by a reduction in 24-hour pad weight after using Flyte for between 2 and 12 weeks.
Flyte is also effective for mild, moderate, and severe SUI. Typical treatment is only five minutes per day for six weeks. Even though Flyte is FDA-cleared for over-the-counter use, the majority of units are prescribed by clinicians. Please visit FlyteTherapy.com for more information.
KEY QUOTES:
“Completing this round is an important step in continuing Pelvital’s unwavering dedication to provide women with innovative solutions for pelvic health, including the treatment of SUI. This funding will play a crucial role in accelerating our commercialization of Flyte with a strong emphasis on expanding payor coverage and enhancing clinical education and clinician awareness.”
– Lydia Zeller, President and CEO of Pelvital
“Joining Pelvital’s Board alongside this investment round is truly an honor. Pier 70 and I are thrilled to be part of this transformational opportunity, as Pelvital’s mission aligns beautifully with our dedication to support disruptive technologies that shake up the status quo in healthcare. Pelvital’s pioneering work is shaping a future where women’s health receives the attention and innovation it deserves with novel medical devices like Flyte.”
– Preetha Ram, PhD, Managing Partner at Pier 70 Ventures, who joins the Pelvital Board of Directors
“We are thrilled for the successful completion of this round as we aim to tackle the most pressing healthcare challenges. Our participation aims to address the chronic underfunding in women’s healthcare. Investing in Flyte, a truly groundbreaking treatment, addresses underserved pelvic health issues like SUI and contributes to raising vital awareness.”
– Oscar Moralez, Founder and Managing Partner of Boomerang Ventures
